COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Swiss Study With Atorvastatin in Hyperlipidemic Patients Measuring LDL-Cholesterol (ACTFAST SWISS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00136942
Recruitment Status : Completed
First Posted : August 29, 2005
Last Update Posted : March 3, 2008
Sponsor:
Information provided by:
Pfizer

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The proportion of patients achieving LDL-C target as defined by Swiss cholesterol recommendations (AGLA-recommendations) across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Condition or disease Intervention/treatment Phase
Hyperlipidemia Drug: Atorvastatin Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 370 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, 6-Week-Treatment, Open-Label Study Assessing The Percentage Of Hyperlipidemic Patients Achieving Low Density Lipoprotein Cholesterol Target With Atorvastatin
Study Start Date : April 2005

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. The proportion of patients achieving LDL-C target as defined by local swiss AGLArecommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Secondary Outcome Measures :
  1. The proportion of patients across different AGLA-categories (primary and secondary prevention) achieving LDL-C target as defined by AGLA-recommendations across starting doses of 10 mg, 20 mg, 40 mg, and 80 mg of atorvastatin.

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Risk factors and diagnosis of dyslipidemia according to the AGLA-recommendations (see appendix B) at screening
  • LDL-C < 6.0 mmol/l
  • Triglyceride level < 5.0 mmol/l.

Exclusion Criteria:

  • Subjects receiving higher than "usual maintenance" doses of Lipid Lowering Therapy (LLT) at screening.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136942


Locations
Layout table for location information
Switzerland
Pfizer Investigational Site
Langenthal, BE, Switzerland
Pfizer Investigational Site
Thun, BE, Switzerland
Pfizer Investigational Site
Binningen, BL, Switzerland
Pfizer Investigational Site
Liestal, BL, Switzerland
Pfizer Investigational Site
Basel, BS, Switzerland
Pfizer Investigational Site
Duedingen, FR, Switzerland
Pfizer Investigational Site
Geneve, GE, Switzerland
Pfizer Investigational Site
Onex, GE, Switzerland
Pfizer Investigational Site
Pfaeffikon, SZ, Switzerland
Pfizer Investigational Site
Siebnen, SZ, Switzerland
Pfizer Investigational Site
Lugano, TI, Switzerland
Pfizer Investigational Site
Malvaglia, TI, Switzerland
Pfizer Investigational Site
Melide, TI, Switzerland
Pfizer Investigational Site
Vezia, TI, Switzerland
Pfizer Investigational Site
Ecublens, VD, Switzerland
Pfizer Investigational Site
Lausanne, VD, Switzerland
Pfizer Investigational Site
Prilly, VD, Switzerland
Pfizer Investigational Site
Unteraegeri, ZG, Switzerland
Pfizer Investigational Site
Zug, ZG, Switzerland
Pfizer Investigational Site
Zuerich, ZH, Switzerland
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00136942    
Other Study ID Numbers: A2581089
First Posted: August 29, 2005    Key Record Dates
Last Update Posted: March 3, 2008
Last Verified: April 2007
Additional relevant MeSH terms:
Layout table for MeSH terms
Hyperlipidemias
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin
Anticholesteremic Agents
 Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors